The effect of age and concomitant treatment with other psychoactive drugs on serum concentrations of citalopram measured with a nonenantioselective method

Therapeutic Drug Monitoring

Volumn 18, Issue 2, 1996, Pages 111-117

  Leinonen, E ^a,d,e   Lepola, U ^a,d   Koponen, H ^b,d   Kinnunen, I ^c  

^a Psychiat Research Clinic of Kuopio   (Finland)

^b Moisio Hospital   (Finland)

^c Niuvanniemen sairaala   (Finland)

^d UNIVERSITY OF HELSINKI   (Finland)

^e Kuopio Psychiatric Research Clinic   (Finland)

Author keywords

Aged; Antidepressive agent; Citalopram; Serum drug concentration

Indexed keywords

ALPRAZOLAM; BENZODIAZEPINE DERIVATIVE; CITALOPRAM; NEUROLEPTIC AGENT; NORCITALOPRAM; PSYCHOTROPIC AGENT; TRICYCLIC ANTIDEPRESSANT AGENT;

ADOLESCENT; ADULT; AGE; AGED; AGING; ARTICLE; CHILD; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG MONITORING; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADULT; AGE FACTORS; AGING; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; BENZODIAZEPINES; CITALOPRAM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; REGRESSION ANALYSIS; SEROTONIN UPTAKE INHIBITORS; SEX FACTORS;

EID: 0029918474     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-199604000-00001     Document Type: Article

References (31)

1. Hyttel J. Citalopram - pharmacological profile of a specific serotonin uptake inhibitor with antidepressant activity. Prog Neuropsychopharmacol Biol Psychiatry 1982;6:277-95.
2. Milne RJ, Goa KL. Citalopram. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness. Drugs 1991;41:450-77.
3. Lepola U, Leinonen E, Turtonen J, Penttinen J. The effects of citalopram in panic disorder and agoraphobia. A pilot study. Nord J Psychiatry 1994;48:13-7.
4. Fredricson-Overö K. Plasma levels of citalopram and metabolites. Lundbeck Rep 1984:350.
5. Bjerkenstedt L, Flyckt L, Fredricson-Overö K, Lingjaerde O. Relations between clinical effects, serum drug concentrations and serotonin uptake inhibition in depressed patients treated with citalopram: a double-blind comparison of three dose levels. Eur J Pharmacol 1985;28:553-7.
6. Fredricson-Overö K. Kinetics of citalopram in man; plasma levels in patients. Prog Neuropsychopharmacol Biol Psychiatry 1982;6:311-8.
7. Gram LF. Plasma level monitoring of tricyclic antidepressant therapy. Clin Pharmacokinet 1975;17:555-63.
8. Preskorn SH, Simpson S. Tricyclic-antidepressant-induced delirium and plasma drug concentration. Am J Psychiatry 1982;139:822-3.
9. Fredricson-Overö K. The role of pharmacokinetics in the development of new drugs: an illustration by studies on citalopram. Thesis, Department of Biochemistry, H. Lundbeck A/S, Copenhagen, 1987.
10. Kragh-Sörensen P, Fredricson-Overö K, Lindegaard Petersen O, Jensen K, Parnas W. The kinetics of citalopram: single and multiple dose studies in man. Acta Pharmacol Toxicol 1981;48:53-60.
11. Sindrup SH, Brösen K, Hansen MGJ, Aaes-Jorgensen T, Overö KF. Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphism. Ther Drug Monit 1993;15:11-7
12. Alvan G, Bechtel P, Iselius L, Gundert-Remy U. Hydroxylation polymorphism of debrisoquine and mephenytoin in European populations. Eur J Clin Pharmacol 1990;39:533-7.
13. Kupfer A, Preisig R. Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man. Eur J Clin Pharmacol 1984;26:753-9.
14. Daniel W, Netter KJ. Alteration of cytochrome P-450 by prolonged administration of imipramine and/or lithium to rats. Naunyn Schmiedebergs Arch Pharmacol 1990;342: 234-40.
15. Linnoila M, George L, Guthrie S, Leventhal B. Effect of alcohol consumption and cigarette smoking on antidepressant levels of depressed patients. Am J Psychiatry 1981;138: 841-2.
16. Brösen K. Isoenzyme specific drug oxidation: genetic polymorphism and drug-drug interactions. Nord J Psychiatry 1993;47(suppl 30):21-6.
17. Gram LF, Hansen MGJ, Sindrup SH, et al. Citalopram: interaction studies with levomepromazine, imipramine, and lithium. Ther Drug Monit 1993;15:18-24.
18. Baettig D, Bondolfi G, Montaldi S, Amey M, Baumann P. Tricyclic antidepressant plasma levels after augmentation with citalopram: a case study. Eur J Clin Pharmacol 1993; 44:403-5.
19. Lin W, Frade P. Simultaneous quantification of eight tricyclic antidepressants in serum by high performance liquid chromatography. Ther Drug Monit 1987;9:448-55.
20. Fredricson-Overö K, Toft B, Christophersen L, Gylding-Sabroe JP. Kinetics of citalopram in elderly patients. Psychopharmacology 1985;86:253-7.
21. Leinonen E, Ylitalo P. Influence of ageing and concurrent psychotropic drugs on demethylation of tertiary tricyclic antidepressants. Int J Geriatr Psychiatry 1991;6:659-66.
22. Gram LF, Fredricson-Overö K. Drug interaction: inhibitory effect of neuroleptics on metabolism of tricyclic antidepressants in man. Br Med J 1972;1:463-5.
23. Warren JA, Ereshefsky L. Therapeutic implications of tricyclic antidepressant plasma levels. Clin Pharmacol 1981;2: 1-14.
24. Brösen K. Cytochrom P450 gen-superfamiliens betydning for laegemidlers kliniske farmakokinetik. Ugeskr Laeger 1991;153:417-22.
25. Crewe HK, Lennard MS, Tucker GT, Woods FR, Haddock RE. The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol 1992;34:262-5.
26. Silverman G, Braithwaite RA. Benzodiazepines and tricyclic antidepressant plasma levels. Br Med J 1973;3:18-20.
27. Otani K, Nordin C, Bertilsson L. No interaction of diazepam on amitriptyline disposition in depressed patients. Ther Drug Monit 1987;9:120-2.
28. Gram LF, Brösen K, Kragh-Sörensen P, Christiansen P. Steady-state plasma levels of E- and Z-10-OH nortriptyline-treated patients: significance of concurrent medication and the sparteine oxidation phenotype. Ther Drug Monit 1989; 11:508-14.
29. Jerling M, Bertilsson L, Sjöqvist F. The use of therapeutic drug monitoring data to document kinetic drug interactions: an example with amitriptyline and nortriptyline. Ther Drug Monit 1994;16:1-12.
30. Antal EJ, Ereshefsky L, Wells B, et al. Multi-center evaluation of the kinetic and clinical interaction of alprazolam and imipramine. Clin Pharmacol Ther 1986;39:178.
31. Hyttel J, Bogeso KP, Perregård J, Sanches C. The pharmacological effect of citalopram residues in the (S)-(+)-enantiomer. J Neural Transm 1992;88:157-60.